Synact Pharma intensifies partnership discussions
Fresh off receiving positive results from a phase IIa study with arthritis candidate AP1189, biotech firm Synact Pharma prepares to look into partnership options.
by christopher due karlsson, translated by daniel pedersen
Synact Pharma is going in with good cards in a hunt for potential partners. Last week, the biotech firm could reveal promising results from a smaller phase IIa study with its drug candidate, AP1189, against arthritis.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
.jpg&w=384&q=75)
